Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition

Journal of Drug Targeting

Volumn 17, Issue 6, 2009, Pages 474-489

  Coyne, C P ^a   Ross, Matt K ^a   Bailey, John G ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

EGFR; Epirubicin; HER2 neu; Immunoconjugate; Mammary carcinoma; P glycoprotein

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBODY CONJUGATE; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; VERAPAMIL; ANTINEOPLASTIC ANTIBIOTIC; CYCLOSPORIN; IMMUNOGLOBULIN G;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG CONJUGATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; IMMUNOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOSPORINE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; P-GLYCOPROTEIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; VERAPAMIL;

EID: 69449106268     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860903012802     Document Type: Article

References (54)

1. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. (2000). A multi-institutional phase II study of BMS-182248-01 (BR96- doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J, 6(2), 78-81.
2. Arteaga CL, O'Neill A, Moulder SP, Pins M, Sparano JA, Sledge GW, Davidson NE. (2008). A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res, 14(19), 6277-6283.
3. Bernstein JL, López-Carrillo L, Wang L. (1999). The epidemiology of Her-2/neu and P53 in breast cancer. Salud Publica Mex, 41(2), S114-S123.
4. Beyer U, Rothen-Rutishauser B, Unger C, Wunderli-Allenspach H, Kratz F. (2001). Difference in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy. Pharm Res, 18, 29-38.
5. Chen X, Yeung TK, Wang Z. (2000). Enhanced drug resistance to cells co-expressing ErbB2 with EGF receptor or ErbB2. Biochem Biophys Res Commun, 277(3), 757-763.
6. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17(9), 2639-2648.
7. Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A. (2008). Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, 16, 362-373.
8. Diener E, Diner UE, Sinha A, Xie S, Vergidis R. (1986). Specific immunosuppression by immunotoxins containing daunomycin. Science, 231(4734), 148-150.
9. Dillman RO, Shawler DL, Johnson DE, Meyer DL, Koziol JA, Frincke JM. (1986). Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res, 46, 4886-4891.
10. Dillman RO, Johnson DE, Ogden J, Beidler D. (1989). Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin- C monoclonal antibody immunoconjugates. Mol Biother, 1, 250-255.
11. Drebin JA, Link VC, Stern DF, Winberg RA, Greene M. (1985). Down- modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41, 697-706.
12. Elledge RM, Clark GM, Chamness GC, Osborne CK. (1994). Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst, 86(9), 705-712.
13. Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ, Goldenberg DM. (2003). Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody- anthracycline drug conjugate. Clin Cancer Res, 9(17), 6567-6571.
14. Hansen HJ, Ong GL, Diril H. (1996). Internalization and catabolism of radiolabeled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J, 320, 293-300.
15. Harwerth IM, Wels W, Schlegel J, Müller M, Hynes NE. (1993). Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer, 68(6), 1140-1145.
16. Herbert C, Norris K, Sauk JJ. (2003). Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates. J Drug Target, 11(2), 101-107.
17. Hurwitz E, Stancovski I, Sela M, Yarden Y. (1995). Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA, 92, 3353-3358.
18. Inoh K, Muramatsu H, Torii S, Ikematsu S, Oda M, Kumai H, Sakuma S, Inui T, Kimura T, Muramatsu T. (2006). Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug. Jpn J Clin Oncol, 36(4), 207-211.
19. Johnson DA, Briggs SL, Gutowski MC, Barton R. (1995). Anti-tumor activity of CC49-doxorubicin immunoconjugates. Anticancer Res, 15(4), 1387-1393.
20. Kaptain S, Tan LK, Chen B. (2001). Her-2/neu and breast cancer. Diagn Mol Pathol, 10(3), 139-152.
21. Kasprzyk PG, Song SU, Di Fiore PP, King CR. (1992). Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res, 52(10), 2771-2776.
22. Klapper LN, Waterman H, Sela M, Yarden Y. (2000). Tumorinhibitory antibodies to HER-2/erbB-2 may act by recruiting c-cbl and enhancing ubiquitination of HER-2. Cancer Res, 60, 3384-3388.
23. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX. (2008). Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res, 68(22), 9280-9290.
24. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. (2008). Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol, 26(12), 1993-1999.
25. Mandler R, Wu C, Sausville EA, Roettinger AJ, Newman DJ, Ho DK, King CR, Yang D, Lippman ME, Landolfi NF, Dadachova E, Brechbiel MW, Waldmann TA. (2000). Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst, 92, 1573-1581.
26. Marches R, Uhr JW. (2004). Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2- overexpressing tumor cells. Int J Cancer, 112(3), 492-501.
27. Mizutani Y, Okada Y, Yoshida O, Fukumoto M, Bonavida B. (1997). Doxorubicin sensitizes human bladder carcinoma cells to Fasmediated cytotoxicity. Cancer, 79(6), 1180-1189.
28. Muldoon LL. (2003). Effect of antigenic heterogeneity on the efficacy of enhanced delivery of antibody-targeted chemotherapy in a human lung cancer intracerebral xenograft models in rats. Neurosurgery, 53(6), 1406-1412.
29. Muldoon LL, Neuwelt EA. (2003). BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. J Neurooncol, 65(11), 49-62.
30. Nicholson RI, Gee JM, Harper ME. (2001). EGFR and cancer prognosis. Eur J Cancer, 37(4), S9-S15.
31. Ogden JR, Leung K, Kunda SA, Telander MW, Avner BP, Liao SK, Thurman GB, Oldham RK. (1989). Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of cis-aconityl-doxorubicin: preparation and in vitro cytotoxicity. Mol Biother, 1(3), 170-174.
32. Page M, Thibeault D, Noel C, Dumas L. (1990). Coupling a preactivated daunorubicin derivative to antibody. A new approach. Anticancer Res, 10, 353-357. (Pubitemid 20187276)
33. Pegram MD, Lopez A, Konecny G, Slamon DJ. (2000). Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol, 27(6 Suppl 11), 21-25; discussion 92-100.
34. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Maneval DA, Slamon DJ. (1998). Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene, 17(17), 2235-2249.
35. Pimm MV, Paul MA, Ogumuyiwa T, Baldwin RW. (1988). Biodistribution and tumour localization of a daunomycin- monoclonal antibody conjugate in nude mice and human tumour xenografts. Cancer Immunol Immunother, 27(3), 267-271.
36. Ravdin PM, Chamness GC. (1995). The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene, 159(1), 19-27.
37. Reményi J, Balázs B, Tóth S, Falus A, Tóth G, Hudecz F. (2003). Isomerdependent daunomycin release and in vitro antitumour effect of cis-aconityl-daunomycin. Biochem Biophys Res Commun, 303(2), 556-561.
38. Remsen LG, Trail PA, Hellstrom I, Hellstrom KE, Neuwelt EA. (2000). Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery, 46(3), 704-709.
39. Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak ID, Griffiths GL, Goldenberg DM. (2005). Anti-CD74 antibody- doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograph and in monkeys. Clin Cancer Res, 11(14), 5257-5264.
40. Sessa C, Valota O, Geroni C. (2007). Ongoing phase I and II studies of novel anthracyclines. Cardiovasc Toxicol, 7(2), 75-79.
41. Shih LB, Goldenberg DM, Xuan H, Lu HW, Mattes MJ, Hall TC. (1994). Internalization of an intact doxorubicin immunoconjugate. Cancer Immunol Immunother, 38(2), 92-98.
42. Sivam GP, Martin PJ, Reisfeld RA, Mueller BM. (1995). Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. Cancer Res, 55(11), 2352-2356.
43. Sjögren HO, Isaksson M, Willner D, Hellström I, Hellström KE, Trail PA. (1997). Antitumor activity of carcinoma-reactive BR96- doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res, 57(20), 4530-4536.
44. Slamon DJ, Clark GM, Wong SG. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science, 235, 177-182.
45. Slamon DJ, Leyland-Jone B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. (2001). Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med, 344(11), 786-792.
46. Sliwkowski MX, Lofgren JA, Lewis GD, Otaling TE, Endly BM, Ox JA. (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol, 26(4 Suppl 12), 60-70.
47. Sorkin A, Di Fiore PP, Carpenter G. (1993). The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. Oncogene, 8(11), 3021-3028.
48. Stan AC, Radu DL, Casares S, Bona CA, Brumeanu TD. (1999). Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen. Cancer Res, 59, 115-121.
49. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE. (1993). Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science, 261, 212-215.
50. Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I. (1997). Effect of linker variation on the stability, potency and efficacy of carcinoma- reactive BR64-doxorubicin immunoconjugates. Cancer Res, 57, 100-105.
51. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 20(3), 719-726.
52. Waterman H, Sabanai I, Geiger B, Yarden Y. (1998). Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem, 273(22), 13819-13827.
53. Yang HM, Reisfeld RA. (1988). Doxorubicin conjugated with monoclonal antibody directed to a human melanoma- associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sci USA, 85, 1189-1193.
54. Zhang YT, Wang NQ, Li N, Liu T, Dong ZW. (1992). The antitumor effect of adriamycin conjugated with monoclonal antibody against gastric cancer in vitro and in vivo. Acta Pharmaceutica Sinica, 27, 325-330.